A Phase 2 interventional study of Denosumab in Cancer, Giant Cell Tumors and Giant Cell Tumor of Bone, sponsored by Amgen. Completed at 33 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-09-22.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To determine how safe denosumab is in treating subjects with giant cell tumor of bone (GCTB)
To determine how safe denosumab is in treating subjects with GCTB
23 studies on the registry are indexed under Giant Cell Tumor of Bone; 7 are open to participants now.
This study's enrollment of 535 is above the median of 43 across 16 interventional studies indexed under Giant Cell Tumor of Bone.
Browse Giant Cell Tumor of Bone studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Giant Cell Tumor of Bone, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
Drug: Denosumab
120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
Also known as: AMG 162, Immunoglobulin G2 human monoclonal antibody to RANK ligand
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
AE defined as any untoward medical occurrence in a clinical trial participant. Serious AE defined as AE that is fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or other significant medical hazard. Severity of AEs assessed according to Common Terminology Criteria for Adverse Events (CTCAE, v3.0) based on the general guideline: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening or disabling; Grade 5: Death related to AE. Investigator assessed AEs for relatedness to study drug. Results are presented for treatment-emergent events (TEAEs) and included all AEs occurring from first dose in initial treatment phase to end of initial treatment phase (or for participants entering retreatment, from first dose in initial treatment phase until end of retreatment phase).
Time frame: From first dose of study drug up to last study visit for treatment-emergent period (a maximum of approximately 111 months).
Number of Participants Who Experienced the Maximum Toxicity Grade (CTCAE Grade ≥ 3) in the Indicated Clinical Chemistry Parameters
Serum samples for clinical chemistry were collected on study day 1 (baseline), day 15, week 5 and each study visit Q4W thereafter until last study visit for the on-study period (ie, until end of initial treatment phase). The parameters included albumin, calcium (albumin-adjusted), creatinine, magnesium and phosphate. Results are presented for number of participants who experienced the maximum toxicity grade for each of these clinical parameters. The maximum toxicity grade experienced by each participant was based on CTCAE, v3.0, and are summarized for Grade 3 and 4. Increases and decreases in relationship to the normal parameter ranges are indicated as 'Above' and 'Below' respectively.
Time frame: Baseline (day 1) up to last study visit for initial treatment phase (median duration approximately 30 months up to a maximum of approximately 109 months).
Time to Disease Progression or Recurrence During the On-Study Period for Cohort 1, Presented as Kaplan-Meier Estimates of Probability
Time to disease progression or recurrence during the on-study period was defined as the time interval (in days) from the date of first dose of study drug to the date of earliest Progressive Disease (PD) during the initial treatment phase. PD was defined as the response of progressive disease, locally recurrent disease or relapse as captured in the Disease Status page of the Case Report Form. If a participant had not had PD by the end of the initial treatment phase date, time to disease progression or recurrence were censored at her/his end of initial treatment phase date. Since median time to disease progression or recurrence for participants in cohort 1 was not reached, Kaplan-Meier estimates for the probability (expressed as a percentage) of participants in cohort 1 to have disease progression or recurrence at months 6, 12, 24, 36 and 60 are presented.
Time frame: From first dose of study drug up to the end of the initial treatment phase (median duration approximately 30 months up to a maximum of approximately 109 months).
Percentage of Participants Without Any On-Study Surgery at Month 6 for Cohort 2
The percentage of participants without any surgery at month 6 was equivalent to the number of participants without any surgery by month 6 divided by the number of cohort 2 participants who had an opportunity to complete 6 months of treatment, expressed as a percentage.
Time frame: At month 6.
Mean Serum Denosumab Trough Concentrations
Blood samples for determination of serum denosumab concentration levels were obtained from participants included in the pharmacokinetic (PK) substudy at baseline (prior to administration of study drug on day 1) and at scheduled time points during the study up to week 25.
Time frame: Blood samples were collected at baseline (day 1), days 8 and 15 and weeks 5, 9, 13 and 25.
Adults and skeletally mature adolescents (≥12 years of age) were enrolled in this open-label single-arm study. The study was conducted at 30 centers in North America, Europe, and Australia from 09 Sep 2008 to study completion on 17 May 2018. The planned study duration for each participant was at least 60 months (following protocol amendment 7).
| Milestone | Cohort 1 (Denosumab 120 mg Q4W) | Cohort 2 (Denosumab 120 mg Q4W) | Cohort 3 (Denosumab 120 mg Q4W) |
|---|---|---|---|
| Started | 268 | 252 | 12 |
| Safety analysis set | 265 | 249 | 12 |
| Efficacy analysis set | 260 | 242 | 11 |
| Completed | 0 | 0 | 0 |
| Not completed | 268 | 252 | 12 |
| Withdrew: Complete resection (as per protocol) | 25 | 121 | 0 |
| Withdrew: Administrative decision | 83 | 42 | 5 |
| Withdrew: End of trial | 32 | 12 | 3 |
| Withdrew: Withdrawal by subject | 33 | 11 | 1 |
| Withdrew: Adverse event | 21 | 19 | 1 |
| Withdrew: Other | 19 | 14 | 1 |
| Withdrew: Disease progression | 21 | 9 | 0 |
| Withdrew: Lost to follow-up | 12 | 14 | 0 |
| Withdrew: Noncompliance | 4 | 6 | 0 |
| Withdrew: Requirement for alternative therapy | 8 | 2 | 0 |
| Withdrew: Pregnancy | 5 | 0 | 1 |
| Withdrew: Death | 5 | 1 | 0 |
| Withdrew: Ineligibility determined | 0 | 1 | 0 |
AE defined as any untoward medical occurrence in a clinical trial participant. Serious AE defined as AE that is fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or other significant medical hazard. Severity of AEs assessed according to Common Terminology Criteria for Adverse Events (CTCAE, v3.0) based on the general guideline: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening or disabling; Grade 5: Death related to AE. Investigator assessed AEs for relatedness to study drug. Results are presented for treatment-emergent events (TEAEs) and included all AEs occurring from first dose in initial treatment phase to end of initial treatment phase (or for participants entering retreatment, from first dose in initial treatment phase until end of retreatment phase).
| Participants | Cohort 1 (Denosumab 120 mg Q4W) | Cohort 2 (Denosumab 120 mg Q4W) | Cohort 3 (Denosumab 120 mg Q4W) |
|---|---|---|---|
| Any TEAE | 260 | 231 | 12 |
| Serious TEAE | 98 | 39 | 5 |
| Fatal TEAE | 8 | 3 | 0 |
| TEAE leading to treatment phase discontinuation | 27 | 24 | 1 |
| TEAE leading to study drug discontinuation | 27 | 23 | 1 |
| CTCAE Grade 3, 4, or 5 | 121 | 59 | 6 |
| Any TEAE related to study drug | 184 | 136 | 9 |
Serum samples for clinical chemistry were collected on study day 1 (baseline), day 15, week 5 and each study visit Q4W thereafter until last study visit for the on-study period (ie, until end of initial treatment phase). The parameters included albumin, calcium (albumin-adjusted), creatinine, magnesium and phosphate. Results are presented for number of participants who experienced the maximum toxicity grade for each of these clinical parameters. The maximum toxicity grade experienced by each participant was based on CTCAE, v3.0, and are summarized for Grade 3 and 4. Increases and decreases in relationship to the normal parameter ranges are indicated as 'Above' and 'Below' respectively.
| Participants | Cohort 1 (Denosumab 120 mg Q4W) | Cohort 2 (Denosumab 120 mg Q4W) | Cohort 3 (Denosumab 120 mg Q4W) |
|---|---|---|---|
| Calcium corrected Grade 3 (Above) | 0 | 1 | 0 |
| Calcium corrected Grade 4 (Above) | 1 | 1 | 0 |
| Calcium corrected Grade 3 (Below) | 1 | 0 | 0 |
| Calcium corrected Grade 4 (Below) | 2 | 0 | 0 |
| Phosphate Grade 3 (Below) | 60 | 41 | 4 |
| Magnesium Grade 3 (Above) | 4 | 5 | 2 |
| Magnesium Grade 3 (Below) | 1 | 0 | 0 |
| Creatinine Grade 3 (Above) | 0 | 1 | 0 |
| Albumin Grade 3 (Below) | 1 | 0 | 0 |
Time to disease progression or recurrence during the on-study period was defined as the time interval (in days) from the date of first dose of study drug to the date of earliest Progressive Disease (PD) during the initial treatment phase. PD was defined as the response of progressive disease, locally recurrent disease or relapse as captured in the Disease Status page of the Case Report Form. If a participant had not had PD by the end of the initial treatment phase date, time to disease progression or recurrence were censored at her/his end of initial treatment phase date. Since median time to disease progression or recurrence for participants in cohort 1 was not reached, Kaplan-Meier estimates for the probability (expressed as a percentage) of participants in cohort 1 to have disease progression or recurrence at months 6, 12, 24, 36 and 60 are presented.
| Percent probability | Cohort 1 (Denosumab 120 mg Q4W) |
|---|---|
| Month 6 | 1.9 (0.3 to 3.6) |
| Month 12 | 4.3 (1.8 to 6.8) |
| Month 24 | 6.1 (3.1 to 9.0) |
| Month 36 | 8.2 (4.6 to 11.8) |
| Month 60 | 11.7 (7.1 to 16.2) |
The percentage of participants without any surgery at month 6 was equivalent to the number of participants without any surgery by month 6 divided by the number of cohort 2 participants who had an opportunity to complete 6 months of treatment, expressed as a percentage.
| Percentage of participants | Cohort 2 (Denosumab 120 mg Q4W) |
|---|---|
| Percentage of Participants Without Any On-Study Surgery at Month 6 for Cohort 2 | 92.0 (87.8 to 95.1) |
Blood samples for determination of serum denosumab concentration levels were obtained from participants included in the pharmacokinetic (PK) substudy at baseline (prior to administration of study drug on day 1) and at scheduled time points during the study up to week 25.
| nanograms / milliliter | Adolescent PK Subset (Denosumab 120 mg Q4W) | Adult PK Subset (Denosumab 120 mg Q4W) |
|---|---|---|
| Day 1 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Day 8 | 11800 ± 4130 | 12000 ± 4300 |
| Day 15 | 21800 ± 5620 | 24200 ± 9050 |
| Week 5 | 30400 ± 6150 | 33500 ± 8970 |
| Week 9 | 25100 ± 6450 | 30000 ± 10300 |
| Week 13 | 22300 ± 6840 | 29100 ± 10000 |
| Week 17 | 23600 ± 4370 | 28300 ± 11600 |
| Week 25 | 22400 ± 6690 | 25400 ± 10800 |
Collected over From first dose of study drug until last study visit; a maximum of approximately 113 months. The planned study duration for each participant was at least 60 months (following protocol amendment 7).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab 120 mg Q4W (All Cohorts) | 26/526 (4.9%) | 176/526 (33.5%) | 480/526 (91.3%) |
| Event | Denosumab 120 mg Q4W (All Cohorts) |
|---|---|
| Osteonecrosis of jawMusculoskeletal and connective tissue disorders | 25/526 |
| Bone giant cell tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 19/526 |
| AnaemiaBlood and lymphatic system disorders | 8/526 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/526 |
| Back painMusculoskeletal and connective tissue disorders | 5/526 |
| SarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/526 |
| DeathGeneral disorders | 4/526 |
| PyrexiaGeneral disorders | 4/526 |
| AppendicitisInfections and infestations | 4/526 |
| Device related infectionInfections and infestations | 4/526 |
| Event | Denosumab 120 mg Q4W (All Cohorts) |
|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 192/526 |
| Back painMusculoskeletal and connective tissue disorders | 154/526 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 146/526 |
| FatigueGeneral disorders | 142/526 |
| HeadacheNervous system disorders | 134/526 |
| NauseaGastrointestinal disorders | 122/526 |
| NasopharyngitisInfections and infestations | 76/526 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 70/526 |
| ToothacheGastrointestinal disorders | 68/526 |
| VomitingGastrointestinal disorders | 66/526 |
The overall baseline population consisted of the 532 participants enrolled into the treatment phase of the study.
| Age, Categorical(Participants) | Cohort 1 (Denosumab 120 mg Q4W) | Cohort 2 (Denosumab 120 mg Q4W) | Cohort 3 (Denosumab 120 mg Q4W) | Total |
|---|---|---|---|---|
| <=18 years | 14 | 14 | 0 | 28 |
| Between 18 and 65 years | 238 | 231 | 12 | 481 |
| >=65 years | 16 | 7 | 0 | 23 |
| Age, Continuous(Years) | Cohort 1 (Denosumab 120 mg Q4W) | Cohort 2 (Denosumab 120 mg Q4W) | Cohort 3 (Denosumab 120 mg Q4W) | Total |
|---|---|---|---|---|
| Mean | 36.4 ± 14.6 | 35.1 ± 13.5 | 36.1 ± 14.9 | 35.8 ± 14.1 |
| Sex: Female, Male(Participants) | Cohort 1 (Denosumab 120 mg Q4W) | Cohort 2 (Denosumab 120 mg Q4W) | Cohort 3 (Denosumab 120 mg Q4W) | Total |
|---|---|---|---|---|
| Female | 154 | 142 | 5 | 301 |
| Male | 114 | 110 | 7 | 231 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 (Denosumab 120 mg Q4W) | Cohort 2 (Denosumab 120 mg Q4W) | Cohort 3 (Denosumab 120 mg Q4W) | Total |
|---|---|---|---|---|
| White or Caucasian | 221 | 208 | 11 | 440 |
| Black or African American | 18 | 12 | 0 | 30 |
| Hispanic or Latino | 13 | 13 | 1 | 27 |
| Asian | 11 | 14 | 0 | 25 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Other | 5 | 4 | 0 | 9 |
| GCTB Disease Type(Participants) | Cohort 1 (Denosumab 120 mg Q4W) | Cohort 2 (Denosumab 120 mg Q4W) | Cohort 3 (Denosumab 120 mg Q4W) | Total |
|---|---|---|---|---|
| Primary resectable | 0 | 167 | 0 | 167 |
| Primary unresectable | 93 | 0 | 2 | 95 |
| Recurrent resectable | 0 | 85 | 0 | 85 |
| Recurrent unresectable | 175 | 0 | 10 | 185 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2008 to primary completion in May 2018, 116 months.
Results were first posted in Dec 2018, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab